LACIE HARRIS: Open Payments
NPI 1366918328 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$221 in 13 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $28 · 2025 $221
Food & beverage: $221
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $66 |
| Novo Nordisk Inc | 2 | $35 |
| Lilly USA, LLC | 2 | $30 |
| GlaxoSmithKline, LLC. | 1 | $29 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $23 |
| ABBVIE INC. | 1 | $15 |
| Corium, LLC | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
Products named: FARXIGA, JARDIANCE, TRELEGY ELLIPTA, Quviviq, Ozempic, Wegovy, AIRSUPRA, QULIPTA.
Industry payments across TX — which companies pay providers there.
